Skip to Content

User Reviews for Bismatrol

The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.

Reviews for Bismatrol

No reviews have yet been submitted. Be the first to review this drug.

More about Bismatrol (bismuth subsalicylate)

Consumer resources

Other brands: Pepto-Bismol, Kaopectate, Pink Bismuth, Maalox Total Relief, ... +4 more

Professional resources

Bismuth Subsalicylate Suspension (FDA)

Other Formulations

Bismatrol Maximum Strength

Related treatment guides

Drug Status

Rx
OTC

Availability Rx and/or OTC

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug

Ulcerative Colitis (MS)

Drug Class

Related Drugs

Helicobacter Pylori Infection omeprazole, amoxicillin, pantoprazole, metronidazole, Protonix, Nexium, More...

Indigestion omeprazole, ranitidine, famotidine, Prilosec, Zantac, Pepcid, More...

Diarrhea Lomotil, Imodium, loperamide, Acidophilus, Florastor, neomycin, More...

Diarrhea, Chronic Imodium, loperamide, Pepto-Bismol, Imodium A-D, bismuth subsalicylate, Kaopectate, More...

2 more conditions...

Bismatrol Images

Pill Imprint GDC 122 (Bismatrol bismuth subsalicylate 262mg)

Bismatrol bismuth subsalicylate 262mg (GDC 122)

Get Email Updates

Subscribe to free Drugs.com newsletters.

By clicking Subscribe, I agree to the Drugs.com Terms & Conditions and Privacy Policy and understand that I may opt out of Drugs.com subscriptions at any time.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Oct 1st, 2018), Cerner Multum™ (updated Oct 2nd, 2018), Wolters Kluwer™ (updated Oct 2nd, 2018) and others. To view content sources and attributions, please refer to our editorial policy.